Targeting Brd4 for cancer therapy: inhibitors and degraders

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Bromodomain-containing protein 4 (Brd4) is implicated in gene expression for cancers and other diseases.
• Inhibiting or downregulating Brd4 shows potential for cancer treatment, making it a significant drug target.
• Br4 inhibitors are under clinical investigation, highlighting their therapeutic relevance.

Purpose of the Study:

• To review recent advancements in small-molecule inhibitors targeting Brd4.
• To discuss the development of Brd4 degraders as a novel therapeutic approach.
• To explore the potential of Brd4-targeted agents in cancer therapy.

Main Methods:

• Literature review of Brd4 inhibitors and degraders.
• Analysis of studies on Brd4's role in cancer development.
• Examination of PROTAC technology for targeted protein degradation.

Main Results:

• Numerous Brd4 inhibitors have been developed and are in clinical trials.
• Selective protein degradation using PROTACs is a promising drug discovery strategy.
• Br4 degraders demonstrate superior anticancer activity compared to traditional inhibitors.

Conclusions:

• Targeting Brd4 with small molecules offers a viable anticancer strategy.
• Brd4 degraders represent a more effective approach than simple inhibition.
• Further research into Brd4-targeted agents holds significant therapeutic promise.